We support pharmaceutical companies and midsize and large consultancies at different steps of an health technology assessment (HTA) submission.
We conduct model adaptations to suit local country requirements based on their local epidemiological, clinical and treatment settings.
We provide independent review of the models developed externally which helps to minimises the risks of technical/formulae errors or methodical errors.
We develop Budget impact models (BIM) to assess the impact on the budget when introducing a new technology or drug.
We conduct systematic literature review (SLR) as well as targeted literature review (TLR) to identify relevant evidence for the decision problem.
We are a boutique consultancy specialising in data analytics, primarily in the domain of Health Economics and Outcomes Research (HEOR), pricing, and market access. Our in-house team of expert health economists and reviewers deliver high-quality work within the stipulated timelines. Generating and communicating key messages effectively lies at the heart of our work culture.